

neonates such as the patient described in the Case Records.

Leslie L. Barton, M.D.

University of Arizona School of Medicine
Tucson, AZ 85724
llb@peds.arizona.edu

1. Case Records of the Massachusetts General Hospital (Case 25-2003). *N Engl J Med* 2003;349:691-700.
2. Wright R, Johnson D, Neumann M, et al. Congenital lymphocytic choriomeningitis virus syndrome: a disease that mimics congenital toxoplasmosis or cytomegalovirus infection. *Pediatrics* 1997;100:126-7. abstract.
3. Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. *Clin Infect Dis* 2001;33:370-4. [Erratum, *Clin Infect Dis* 2001;33:1445.]
4. Barton LL, Mets MB, Beauchamp CL. Lymphocytic choriomeningitis virus: emerging fetal teratogen. *Am J Obstet Gynecol* 2002;187:1715-6.

DR. MODLIN REPLIES: Dr. Barton and colleagues have written several articles that remind us of the impor-

tance of lymphocytic choriomeningitis virus as a vertically transmitted viral pathogen.¹⁻⁴ However, this virus is very rarely a cause of hepatomegaly, hyperbilirubinemia, or thrombocytopenia,² all of which were prominent presenting manifestations in the case under discussion.

John F. Modlin, M.D.

Dartmouth-Hitchcock Medical Center
Lebanon, NH 03756
john.modlin@dartmouth.edu

1. Mets MB, Barton LL, Khan AS, Ksiazek TG. Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. *Am J Ophthalmol* 2000;130:209-15.
2. Barton LL, Mets MB. Congenital lymphocytic choriomeningitis virus infection: decade of rediscovery. *Clin Infect Dis* 2001;33:370-4. [Erratum, *Clin Infect Dis* 2001;33:1445.]
3. Barton LL, Peters CJ, Ksiazek TG. Lymphocytic choriomeningitis virus: an unrecognized teratogenic pathogen. *Emerg Infect Dis* 1995;1:152-3.
4. Barton LL, Mets MB, Beauchamp CL. Lymphocytic choriomeningitis virus: emerging fetal teratogen. *Am J Obstet Gynecol* 2002;187:1715-6.

Aristolochic Acid, an Herbal Carcinogen, Sold on the Web after FDA Alert

TO THE EDITOR: In 2001, the Food and Drug Administration (FDA) issued warnings and an import alert that herbal products are unsafe if they contain or are suspected to contain aristolochic acid.¹ A report in the *Journal* in 2000 described a cohort of 105 patients in whom rapidly progressive nephropathy developed after they had been given an herbal weight-loss product containing aristolochic acid by a Belgian clinic.² Because of a suspected association between aristolochic acid and urothelial carcinoma, 39 patients with end-stage renal disease underwent prophylactic removal of the kidneys and ureters; urothelial carcinoma was diagnosed in 18 of them. Aristolochic acid nephropathy has been reported in eight other countries, and associated urinary tract cancer has been reported in two.³ The International Agency for Research on Cancer classifies products containing aristolochia species as human carcinogens.⁴

Despite the actions of the FDA, in 2003 we identified 19 products containing aristolochic acid and 95 products suspected to contain aristolochic acid for sale on the Web. These products and approximately 100 related Web sites are listed on the Web at <http://potency.berkeley.edu/aristolochicacid.html>.

These herbal products should not be available but are sold on U.S. Web sites for gastrointestinal symptoms, weight loss, cough, and immune stimulation.

The toxicologic evidence of the risks associated with aristolochic acid is strong. In 1982, tumors were rapidly induced in rats at low doses⁵; aristolochic acid is among the most potent 2 percent of the carcinogens in our Carcinogenic Potency Database.⁶ It is mutagenic, forms DNA adducts in humans, and is carcinogenic in mice.³ In rabbits, aristolochic acid induces nephrotoxic effects, the same DNA adducts in kidney as in humans, and urothelial tumors.³

The availability of aristolochic acid-containing products on the Web two years after an FDA alert was issued reveals a serious flaw in the safety protection afforded the public. Under the Dietary Supplement Health Education Act, herbal products do not require FDA approval of efficacy or safety before marketing, and products are not registered. In addition, the Web is a marketing tool with low barriers to entry (anyone can set up a Web site inexpensively). The failure to protect the public from the imminent hazard of aristolochic acid indicates that there is an urgent need to remove these products from the Web

and to develop a policy that addresses Web sales of hazardous herbal products.

Lois Swirsky Gold, Ph.D.
Thomas H. Slone, M.S.

University of California, Berkeley
Berkeley, CA 94720
cpdb@potency.berkeley.edu

1. Food and Drug Administration. Dietary supplements: aristolochic acid. (Accessed September 25, 2003, at <http://www.cfsan.fda.gov/~dms/ds-bot.html>.)
2. Nortier JL, Muniz Martinez M-C, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (*Aristolochia fangchi*). *N Engl J Med* 2000;342:1686-92.

3. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. *Mutagenesis* 2002;17:265-77.
4. Some traditional herbal medicines, some mycotoxins, naphthalene and styrene. Vol. 82 of IARC monographs on the evaluation of carcinogenic risk of chemicals to humans. Lyons, France: IARC Press, 2002.
5. Mengs U, Lang W, Poch J-A. The carcinogenic action of aristolochic acid in rats. *Arch Toxicol* 1982;51:107-19.
6. Gold LS, Zeiger E, eds. Handbook of carcinogenic potency and genotoxicity databases. Boca Raton, Fla.: CRC Press, 1997. (Also available at <http://potency.berkeley.edu/>.)

Correspondence Copyright © 2003 Massachusetts Medical Society.

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following: •Letters in reference to a *Journal* article must not exceed 175 words (excluding references), must be received within three weeks after publication of the article, and must be submitted over the Internet at secure.nejm.org/letters. Letters not related to a *Journal* article must not exceed 400 words and may be submitted over the Internet or sent, typewritten and triple-spaced, by mail. •A letter can have no more than five references and one figure or table. •A letter can be signed by no more than three authors. •Financial associations or other possible conflicts of interest must be disclosed. (Such disclosures will be published with the letters. For authors of *Journal* articles who are responding to letters, this information appears in the original articles.) •Include your full mailing address, telephone number, fax number, and e-mail address with your letter.

Our address: **Letters to the Editor • New England Journal of Medicine • 10 Shattuck St. • Boston, MA 02115**

Our Web address: **secure.nejm.org/letters**

Our fax numbers: **617-739-9864 and 617-734-4457**

We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. Letters that do not adhere to these instructions will not be considered. Rejected letters and figures will not be returned. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the *Journal's* various print and electronic publications and in collections, revisions, and any other form or medium.